ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Metrics to compare | ABVC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVCPeersSector | |
---|---|---|---|---|
P/E Ratio | −15.4x | −1.5x | −0.5x | |
PEG Ratio | −0.18 | −0.03 | 0.00 | |
Price/Book | 8.3x | 1.6x | 2.6x | |
Price / LTM Sales | 87.9x | 10.2x | 3.3x | |
Upside (Analyst Target) | - | 316.7% | 45.1% | |
Fair Value Upside | Unlock | 36.7% | 7.4% | Unlock |